Cargando…

A Practical Guide to Immunoassay Method Validation

Biochemical markers have a central position in the diagnosis and management of patients in clinical medicine, and also in clinical research and drug development, also for brain disorders, such as Alzheimer’s disease. The enzyme-linked immunosorbent assay (ELISA) is frequently used for measurement of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Andreasson, Ulf, Perret-Liaudet, Armand, van Waalwijk van Doorn, Linda J. C., Blennow, Kaj, Chiasserini, Davide, Engelborghs, Sebastiaan, Fladby, Tormod, Genc, Sermin, Kruse, Niels, Kuiperij, H. Bea, Kulic, Luka, Lewczuk, Piotr, Mollenhauer, Brit, Mroczko, Barbara, Parnetti, Lucilla, Vanmechelen, Eugeen, Verbeek, Marcel M., Winblad, Bengt, Zetterberg, Henrik, Koel-Simmelink, Marleen, Teunissen, Charlotte E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2015
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4541289/ https://www.ncbi.nlm.nih.gov/pubmed/26347708 http://dx.doi.org/10.3389/fneur.2015.00179

Ejemplares similares

Multicenter Analytical Validation of Aβ40 Immunoassays
por: van Waalwijk van Doorn, Linda J. C., et al.
Publicado: (2017)

Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia
por: Chiasserini, Davide, et al.
Publicado: (2017)

White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation
por: Teunissen, Charlotte E., et al.
Publicado: (2018)

Preanalytical Confounding Factors in the Analysis of Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: The Issue of Diurnal Variation
por: Cicognola, Claudia, et al.
Publicado: (2015)

The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases
por: Reijs, Babette L. R., et al.
Publicado: (2015)

No diurnal variation of classical and candidate biomarkers of Alzheimer’s disease in CSF
por: Cicognola, Claudia, et al.
Publicado: (2016)

Critical Steps to be Taken into Consideration Before Quantification of β-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment
por: Vanderstichele, Hugo Marcel, et al.
Publicado: (2019)

A First Tetraplex Assay for the Simultaneous Quantification of Total α-Synuclein, Tau, β-Amyloid(42) and DJ-1 in Human Cerebrospinal Fluid
por: Kruse, Niels, et al.
Publicado: (2016)

A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias
por: Bolsewig, Katharina, et al.
Publicado: (2022)

New CSF biomarkers on the block
por: Teunissen, Charlotte E, et al.
Publicado: (2016)

Cerebrospinal fluid neurogranin/β-site APP-cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease
por: Kirsebom, Bjørn-Eivind, et al.
Publicado: (2018)

Measurement of CSF core Alzheimer disease biomarkers for routine clinical diagnosis: do fresh vs frozen samples differ?
por: Bellomo, Giovanni, et al.
Publicado: (2020)

A multifunctional ELISA to measure oxidised proteins: oxPin1 in Alzheimer's brain as an example
por: Herbert, Megan K., et al.
Publicado: (2015)

Bioinformatics tools and data resources for assay development of fluid protein biomarkers
por: Waury, Katharina, et al.
Publicado: (2022)

Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis
por: Eusebi, Paolo, et al.
Publicado: (2016)

Cerebrospinal fluid biomarkers for the diagnosis and prognosis of Parkinson’s disease: protocol for a systematic review and individual participant data meta-analysis
por: Eusebi, Paolo, et al.
Publicado: (2017)

Phosphatidylethanolamine Binding Protein 1 (PEBP1) in Alzheimer’s Disease: ELISA Development and Clinical Validation
por: Wojdała, Anna Lidia, et al.
Publicado: (2022)

TDP-43 as a possible biomarker for frontotemporal lobar degeneration: a systematic review of existing antibodies
por: Goossens, Joery, et al.
Publicado: (2015)

Potential sources of interference on Abeta immunoassays in biological samples
por: Vanderstichele, Hugo, et al.
Publicado: (2012)

Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry
por: Lewczuk, Piotr, et al.
Publicado: (2017)

MicroRNA-29a Is a Candidate Biomarker for Alzheimer’s Disease in Cell-Free Cerebrospinal Fluid
por: Müller, Mareike, et al.
Publicado: (2015)

Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer’s disease patients
por: Bridel, Claire, et al.
Publicado: (2017)

Combined Analysis of CSF Tau, Aβ42, Aβ1–42% and Aβ1–40(ox)% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia
por: Bibl, Mirko, et al.
Publicado: (2010)

Reduced Influence of apoE on Aβ43 Aggregation and Reduced Vascular Aβ43 Toxicity as Compared with Aβ40 and Aβ42
por: Jäkel, Lieke, et al.
Publicado: (2020)

The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer’s Disease
por: De Vos, Ann, et al.
Publicado: (2016)

Limitations of the hCMEC/D3 cell line as a model for Aβ clearance by the human blood‐brain barrier
por: Biemans, Elisanne A.L.M., et al.
Publicado: (2016)

Status of Current Biofluid Biomarkers in Parkinson's Disease
por: Mollenhauer, Brit
Publicado: (2023)

Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer’s disease and frontotemporal dementia
por: Das, Shreyasee, et al.
Publicado: (2023)

Neurogranin and tau in cerebrospinal fluid and plasma of patients with acute ischemic stroke
por: De Vos, Ann, et al.
Publicado: (2017)

Evidence for Elevated Cerebrospinal Fluid ERK1/2 Levels in Alzheimer Dementia
por: Spitzer, Philipp, et al.
Publicado: (2011)

No Plasmatic Proteomic Signature at Clinical Disease Onset Associated With 11 Year Clinical, Cognitive and MRI Outcomes in Relapsing-Remitting Multiple Sclerosis Patients
por: Bridel, Claire, et al.
Publicado: (2018)

Contactin-1 and contactin-2 in cerebrospinal fluid as potential biomarkers for axonal domain dysfunction in multiple sclerosis
por: Chatterjee, Madhurima, et al.
Publicado: (2018)

Patient-Specific Pluripotent Stem Cells in Neurological Diseases
por: Durnaoglu, Serpen, et al.
Publicado: (2011)

Cerebrospinal Fluid Biomarkers and Prediction of Conversion in Patients with Mild Cognitive Impairment: 4-Year Follow-Up in a Routine Clinical Setting
por: Lanari, Alessia, et al.
Publicado: (2009)

Cerebrospinal fluid in Alzheimer's: A precious tool
por: Parnetti, Lucilla, et al.
Publicado: (2016)

Cerebrospinal fluid markers in Creutzfeldt-Jakob disease
por: Skinningsrud, Anders, et al.
Publicado: (2008)

Biomarkers for the Diagnosis of Alzheimer’s Disease in Clinical Practice: The Role of CSF Biomarkers during the Evolution of Diagnostic Criteria
por: Dulewicz, Maciej, et al.
Publicado: (2022)

Selective loss of glucocerebrosidase activity in sporadic Parkinson’s disease and dementia with Lewy bodies
por: Chiasserini, Davide, et al.
Publicado: (2015)

Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer’s disease
por: Majbour, Nour K., et al.
Publicado: (2017)

The Endotoxin-Induced Neuroinflammation Model of Parkinson's Disease
por: Tufekci, Kemal Ugur, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_93rgq9pk70qipktlk3lr7bm05f